Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as Second Line Therapy.
- Author:
Duk Joo LEE
1
;
Ho Suk OH
;
Jung Hye CHOI
;
Young Yeul LEE
;
In Soon KIM
;
Myung Ju AHN
Author Information
1. Department of Internal Medicine, College of Medicine, Hanyang University, Korea. jhcmd@hanyang.ac.kr
- Publication Type:Original Article
- Keywords:
Oxaliplatin;
5-fluorouracil;
Leucovorin;
Colorectal neoplasms
- MeSH:
Anemia;
Colorectal Neoplasms*;
Drug Therapy;
Drug Therapy, Combination;
Female;
Fluorouracil*;
Follow-Up Studies;
Humans;
Leucovorin*;
Liver;
Lung;
Neutropenia;
Ovary;
Peripheral Nervous System Diseases;
Peritoneum;
Vomiting
- From:Cancer Research and Treatment
2006;38(4):201-205
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The purpose of the study was to assess the efficacy and safety of biweekly oxaliplatin in combination with leucovorin (LV)-modulated bolus plus infusion of 5-fluorouracil (5-FU) in patients with relapsed or metastatic colorectal cancer (CRC) as a second line therapy. MATERIALS AND METHODS: Between November 2002 and October 2005, 26 patients with histologically confirmed relapsed or metastatic CRC were enrolled. All patients were previously treated with irinotecan-based combination chemotherapy. The chemotherapy regimen consisted of oxaliplatin 85 mg/m2 on day 1; LV 200 mg/m2 on days 1 and 2; and 5-FU 400 mg/m2 bolus IV with 600 mg/m2 with a 22-hour infusion on days 1 and 2 every 2 weeks. RESULTS: The median age of the 26 patients was 50.5 years (range, 31~72). Their metastatic sites included: the liver (42.3%), peritoneum (26.9%), lung (23.1%) and ovary (7.7%). Twenty five patients were evaluated for their response. Four patients achieved partial responses and 15 patients had stable disease. The overall response rate was 16% (95% confidence interval; 1.7~30.3%). The median follow-up duration for the surviving patients was 7.4 months (range, 2.08~21.2). Median overall survival (OS) and 1-year OS rates were 16.7 months and 63.9%, respectively. The most common hematological toxicities were: NCI grade I/II leucopenia (49.3%), grade I/II neutropenia (41%) and grade I/II anemia (65.2%). The main non-hematological toxicities were: grade I/II peripheral neuropathy (16.1% and 21.5%, respectively) and nausea/ vomiting (23.6%/18.5%). There was no life-threatening toxicity. CONCLUSION: The oxaliplatin, 5-FU and LV combination chemotherapy, scheduled as a biweekly protocol, was effective and well tolerated in the treatment of relapsed or metastatic colorectal cancer patients as second line chemotherapy.
